XOMA Royalty (XOMA) Receivables - Other (2011 - 2024)

XOMA Royalty (XOMA) reported Receivables - Other of $12.7 million for Q3 2024, down 10.92% sequentially from $14.3 million in Q2 2024.

XOMA Royalty (XOMA) Receivables - Other (2011 - 2024) Analysis & Trends

XOMA Royalty (XOMA) has 10 years of Receivables - Other data on file, last reported at $12.7 million in Q3 2024.

For the quarter ending Q3 2024, Receivables - Other changed N/A year-over-year to $12.7 million; the trailing twelve-month figure through Sep 2024 stood at $12.7 million (changed N/A YoY), and the FY2023 full-year result was $14.2 million, up 491.67% from the prior year.
Receivables - Other retreated to $12.7 million in Q3 2024, from $14.3 million in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $14.3 million in Q2 2024 to a low of $2.4 million in Q4 2022.
A 3-year average of $7.7 million and a median of $5.0 million in 2023 frame the typical range for Receivables - Other.
Peak annual rise in Receivables - Other reached 491.67% in 2023, while the deepest fall reached 100.0% in 2023.
Tracing XOMA's Receivables - Other over 3 years: stood at $2.4 million in 2022, then surged by 491.67% to $14.2 million in 2023, then declined by 10.56% to $12.7 million in 2024.
Business Quant data shows XOMA's Receivables - Other at $12.7 million in Q3 2024, $14.3 million in Q2 2024, and $3.0 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	XOMA Royalty	478.42 Mn	412.34 Mn	-

Download Data